Patient demographics for 110 recipients of umbilical cord blood transplantation
| Characteristics . | . |
|---|---|
| Patients, no. | 110 |
| Age, y, median (range) | 51 (17-69) |
| Male, no. (%) | 65 (59) |
| Weight in kg, median (range) | 76 (50-134) |
| Recipient CMV-positive, no. (%) | 55 (50) |
| Acute leukemia | |
| CR1/CR2, no. (%) | 35 (31.8) |
| CR3=/active disease, no. (%) | 6 (5.5) |
| CML | |
| CP1, no. (%) | 2 (1.8) |
| Others, no. (%) | 5 (4.5) |
| MDS | |
| RA, no. (%) | 1 (0.9) |
| RARS, no. (%) | 2 (1.8) |
| RAEB, no. (%) | 7 (6.5) |
| CMML, no. (%) | 3 (2.7) |
| Secondary, no. (%) | 1 (0.9) |
| Unclassified, no. (%) | 1 (0.9) |
| Myelofibrosis, no. (%) | 2 (1.8) |
| Hodgkin lymphoma | |
| CRU, no. (%) | 1 (0.9) |
| PR, no. (%) | 3 (2.7) |
| Relapsed/refractory, no. (%) | 2 (1.8) |
| NHL:DLC/mantle-cell/other | |
| CR2, no. (%) | 1 (0.9) |
| PR, no. (%) | 11 (10.0) |
| Relapsed/refractory, no. (%) | 2 (1.8) |
| NHL: follicular/CLL | |
| CR1, no. (%) | 2 (1.8) |
| PR, no. (%) | 7 (6.3) |
| Relapsed/refractory, no. (%) | 10 (9.1) |
| Multiple myeloma: PR, no. (%) | 2 (1.8) |
| Aplastic anemia, no. (%) | 4 (3.6) |
| ATG in the conditioning regimen, no. (%) | 39 (35) |
| Indication for nonmyeloablative transplantation | |
| Age greater than 45 years, no. (%) | 82 (74.6) |
| Presence of high risk clinical features, no. (%)* | 29 (26.3) |
| Karnofsky 50% to 80%, no. (%) | 21 (19.1) |
| Extensive prior therapy, no. (%)† | 33 (30.0) |
| Serious organ dysfunction, no. (%)‡ | 8 (7.2) |
| Prior autologous transplantation, no. (%) | 20 (18.1) |
| Recent mold infection, no. (%)§ | 14 (12.7) |
| Characteristics . | . |
|---|---|
| Patients, no. | 110 |
| Age, y, median (range) | 51 (17-69) |
| Male, no. (%) | 65 (59) |
| Weight in kg, median (range) | 76 (50-134) |
| Recipient CMV-positive, no. (%) | 55 (50) |
| Acute leukemia | |
| CR1/CR2, no. (%) | 35 (31.8) |
| CR3=/active disease, no. (%) | 6 (5.5) |
| CML | |
| CP1, no. (%) | 2 (1.8) |
| Others, no. (%) | 5 (4.5) |
| MDS | |
| RA, no. (%) | 1 (0.9) |
| RARS, no. (%) | 2 (1.8) |
| RAEB, no. (%) | 7 (6.5) |
| CMML, no. (%) | 3 (2.7) |
| Secondary, no. (%) | 1 (0.9) |
| Unclassified, no. (%) | 1 (0.9) |
| Myelofibrosis, no. (%) | 2 (1.8) |
| Hodgkin lymphoma | |
| CRU, no. (%) | 1 (0.9) |
| PR, no. (%) | 3 (2.7) |
| Relapsed/refractory, no. (%) | 2 (1.8) |
| NHL:DLC/mantle-cell/other | |
| CR2, no. (%) | 1 (0.9) |
| PR, no. (%) | 11 (10.0) |
| Relapsed/refractory, no. (%) | 2 (1.8) |
| NHL: follicular/CLL | |
| CR1, no. (%) | 2 (1.8) |
| PR, no. (%) | 7 (6.3) |
| Relapsed/refractory, no. (%) | 10 (9.1) |
| Multiple myeloma: PR, no. (%) | 2 (1.8) |
| Aplastic anemia, no. (%) | 4 (3.6) |
| ATG in the conditioning regimen, no. (%) | 39 (35) |
| Indication for nonmyeloablative transplantation | |
| Age greater than 45 years, no. (%) | 82 (74.6) |
| Presence of high risk clinical features, no. (%)* | 29 (26.3) |
| Karnofsky 50% to 80%, no. (%) | 21 (19.1) |
| Extensive prior therapy, no. (%)† | 33 (30.0) |
| Serious organ dysfunction, no. (%)‡ | 8 (7.2) |
| Prior autologous transplantation, no. (%) | 20 (18.1) |
| Recent mold infection, no. (%)§ | 14 (12.7) |
CR1 indicates first complete remission; CR2, second complete remission; CR3+, third or later complete remission; CML, chronic myeloid leukemia; CP1, first chronic phase; CRU, complete remission undetermined; MDS, myelodysplastic syndrome; RA, refractory anemia; RARS, refractory anemia with ringed sideroblasts; RAEB, refractory anemia with excess of blasts; CMML, chronic myelomonocytic leukemia; PR, partial remission; NHL, non-Hodgkin lymphoma; DLC, diffuse large cell; and CLL, chronic lymphocytic leukemia.
Presence of pre-existing high-risk clinical features was defined as a Karnofsky score less than or equal to 60, presence of serious organ dysfunction, and invasive mold infection within 4 months of transplantation.
Extensive prior therapy was defined as prior autologous transplantation, more than 12 months alkylator-based chemotherapy, or more than 6 months alkylator-based chemotherapy with extensive radiation.
Serious organ dysfunction was defined as bilirubin between more than 2 times above upper normal limit, transaminases more than 2 times above the upper normal limit, corrected DLCO 50% or less of predicted, and ejection fraction less than 45%.
Within 4 months of transplantation.